[{"id":"164a11b6-0a88-4e66-b764-a14af3e3880e","acronym":"NCI-2018-01054","url":"https://clinicaltrials.gov/study/NCT03360721","created_at":"2021-01-18T16:35:16.869Z","updated_at":"2025-02-25T12:26:48.752Z","phase":"Phase 2","brief_title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03360721 - NCI-2018-01054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" AR overexpression • AR expression • AR-V7 expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR overexpression • AR expression • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-24"},{"id":"d77f7e27-d759-4800-bb9d-f2404753c9ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT06222593","created_at":"2024-01-24T15:19:20.942Z","updated_at":"2025-02-25T14:10:34.092Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC","source_id_and_acronym":"NCT06222593","lead_sponsor":"State University of New York at Buffalo","biomarkers":" AR • KLK2","pipe":" | ","alterations":" AR expression • KLK2 expression","tags":["AR • KLK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • KLK2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-17"},{"id":"db437829-c154-4ef1-a95d-32ea4e2d953d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02676986","created_at":"2021-01-18T13:03:06.360Z","updated_at":"2025-02-25T15:33:36.075Z","phase":"Phase 2","brief_title":"Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer","source_id_and_acronym":"NCT02676986","lead_sponsor":"Queen Mary University of London","biomarkers":" HER-2 • ER • AR","pipe":" | ","alterations":" AR positive • AR expression","tags":["HER-2 • ER • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive • AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 221","initiation":"Initiation: 08/10/2015","start_date":" 08/10/2015","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2024-07-04"},{"id":"2af189ad-e994-4b2d-962e-d2e2497fe4a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02750358","created_at":"2021-01-18T13:28:26.255Z","updated_at":"2025-02-25T15:33:40.453Z","phase":"Phase 2","brief_title":"Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer","source_id_and_acronym":"NCT02750358","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" AR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/19/2016","start_date":" 05/19/2016","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-21"},{"id":"5ab208a3-026d-4e92-9792-740f22b8d7f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02955394","created_at":"2021-01-18T14:31:11.528Z","updated_at":"2024-07-02T16:34:36.780Z","phase":"Phase 2","brief_title":"Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer","source_id_and_acronym":"NCT02955394","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" AR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 09/21/2017","start_date":" 09/21/2017","primary_txt":" Primary completion: 02/17/2023","primary_completion_date":" 02/17/2023","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-06-10"},{"id":"5c645a31-d350-4231-926f-0a8a1ea0892f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04573231","created_at":"2021-01-18T21:50:12.443Z","updated_at":"2024-07-02T16:35:02.152Z","phase":"Phase 2","brief_title":"Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer","source_id_and_acronym":"NCT04573231","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" HER-2 • FOLH1","pipe":" | ","alterations":" HER-2 negative • AR expression • FOLH1 expression","tags":["HER-2 • FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR expression • FOLH1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-05-22"},{"id":"14331834-8f2b-4486-822e-55a18617a637","acronym":"","url":"https://clinicaltrials.gov/study/NCT02007512","created_at":"2021-01-18T09:09:59.824Z","updated_at":"2024-07-02T16:35:07.270Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT02007512","lead_sponsor":"Pfizer","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" AR expression","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • exemestane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 12/13/2013","start_date":" 12/13/2013","primary_txt":" Primary completion: 09/23/2016","primary_completion_date":" 09/23/2016","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-26"},{"id":"82221c90-c600-4f21-b83b-c37cc17c3f3a","acronym":"ENPAC","url":"https://clinicaltrials.gov/study/NCT02684227","created_at":"2021-01-18T13:05:28.879Z","updated_at":"2024-07-02T16:35:33.421Z","phase":"Phase 2","brief_title":"Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer","source_id_and_acronym":"NCT02684227 - ENPAC","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" AR","pipe":" | ","alterations":" AR expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 08/24/2016","start_date":" 08/24/2016","primary_txt":" Primary completion: 09/27/2023","primary_completion_date":" 09/27/2023","study_txt":" Completion: 09/27/2023","study_completion_date":" 09/27/2023","last_update_posted":"2023-10-16"},{"id":"266c441e-217f-4fdb-b291-e341689e4674","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628988","created_at":"2021-01-19T20:36:06.920Z","updated_at":"2024-07-02T16:35:37.303Z","phase":"Phase 1","brief_title":"A Study of CC-90011 and Comparators in Participants With Prostate Cancer","source_id_and_acronym":"NCT04628988","lead_sponsor":"Celgene","biomarkers":" AR","pipe":" | ","alterations":" AR expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone • pulrodemstat (CC-90011)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 07/28/2021","start_date":" 07/28/2021","primary_txt":" Primary completion: 05/26/2023","primary_completion_date":" 05/26/2023","study_txt":" Completion: 05/26/2023","study_completion_date":" 05/26/2023","last_update_posted":"2023-09-13"},{"id":"8a8c1097-2351-4c75-bfab-fe99e5d38d48","acronym":"","url":"https://clinicaltrials.gov/study/NCT02605486","created_at":"2021-01-17T17:26:08.635Z","updated_at":"2024-07-02T16:35:44.260Z","phase":"Phase 1/2","brief_title":"Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)","source_id_and_acronym":"NCT02605486","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" AR expression","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • bicalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 11/11/2015","start_date":" 11/11/2015","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-06-30"},{"id":"c4a0b705-eaf6-4b92-b7d5-0494cb3141d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01974765","created_at":"2023-04-28T19:04:52.968Z","updated_at":"2024-07-02T16:35:49.395Z","phase":"Phase 2","brief_title":"Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies","source_id_and_acronym":"NCT01974765","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" AR","pipe":" | ","alterations":" AR expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 11/05/2013","start_date":" 11/05/2013","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 02/28/2022","study_completion_date":" 02/28/2022","last_update_posted":"2023-04-28"},{"id":"0d7ff3cc-6422-42b2-8b6f-d9a6554297bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03123978","created_at":"2021-07-07T15:54:06.603Z","updated_at":"2024-07-02T16:35:49.518Z","phase":"Phase 1","brief_title":"Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT03123978","lead_sponsor":"Mamta Parikh","biomarkers":" AR","pipe":" | ","alterations":" AR expression • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • niclosamide"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/09/2017","start_date":" 01/09/2017","primary_txt":" Primary completion: 01/14/2022","primary_completion_date":" 01/14/2022","study_txt":" Completion: 04/19/2022","study_completion_date":" 04/19/2022","last_update_posted":"2023-04-26"},{"id":"e6fa6f5f-f47f-4e45-ac2a-8106517e9c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT04021394","created_at":"2021-01-18T19:44:45.886Z","updated_at":"2024-07-02T16:35:51.538Z","phase":"","brief_title":"Influence of EMT on CTCs and Disease Progression in Prostate Cancer","source_id_and_acronym":"NCT04021394","lead_sponsor":"Lawson Health Research Institute","biomarkers":" CDH1 • EPCAM • CDH2 • ZEB1","pipe":" | ","alterations":" AR expression • CDH1 expression • EPCAM expression • ZEB1 expression","tags":["CDH1 • EPCAM • CDH2 • ZEB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • CDH1 expression • EPCAM expression • ZEB1 expression"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 04/27/2021","primary_completion_date":" 04/27/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-04-04"},{"id":"f26d04a5-ba02-44dc-93a7-e1a000a2c333","acronym":"","url":"https://clinicaltrials.gov/study/NCT02012296","created_at":"2021-01-18T09:11:50.301Z","updated_at":"2024-07-02T16:36:07.346Z","phase":"Phase 1/2","brief_title":"Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer","source_id_and_acronym":"NCT02012296","lead_sponsor":"University of Chicago","biomarkers":" AR • NR3C1","pipe":" | ","alterations":" AR expression","tags":["AR • NR3C1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Mifeprex (mifepristone)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 12/13/2013","start_date":" 12/13/2013","primary_txt":" Primary completion: 06/10/2019","primary_completion_date":" 06/10/2019","study_txt":" Completion: 08/01/2020","study_completion_date":" 08/01/2020","last_update_posted":"2022-07-13"},{"id":"2b5e323f-9e4a-4d5e-924a-a741c944cff4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01990209","created_at":"2021-07-13T22:53:46.156Z","updated_at":"2025-02-25T14:56:51.373Z","phase":"Phase 2","brief_title":"Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)","source_id_and_acronym":"NCT01990209","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" PGR","pipe":" | ","alterations":" AR expression","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e orteronel (TAK 700)"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2022-06-30"},{"id":"b6e1732a-94ba-4987-89c6-fdaa0b335f2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05404334","created_at":"2022-06-03T11:55:35.300Z","updated_at":"2024-07-02T16:36:09.313Z","phase":"","brief_title":"of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation","source_id_and_acronym":"NCT05404334","lead_sponsor":"Banaras Hindu University","biomarkers":" BRCA1 • BRCA2 • AR • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • AR expression • BRCA1 mutation + BRCA2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • AR • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • AR expression • BRCA1 mutation + BRCA2 mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-06-06"},{"id":"f1591253-3f87-4a5a-bd87-ff8a7cea050d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02138383","created_at":"2021-01-18T09:55:34.655Z","updated_at":"2025-02-25T15:33:10.506Z","phase":"Phase 1","brief_title":"Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer","source_id_and_acronym":"NCT02138383","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" AR","pipe":" | ","alterations":" AR expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Xtandi (enzalutamide) • albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 05/22/2014","start_date":" 05/22/2014","primary_txt":" Primary completion: 12/15/2016","primary_completion_date":" 12/15/2016","study_txt":" Completion: 10/07/2019","study_completion_date":" 10/07/2019","last_update_posted":"2021-08-17"},{"id":"1900325e-e2d0-44ec-828f-b3c2325be47b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02544997","created_at":"2021-01-18T12:18:45.719Z","updated_at":"2024-07-02T16:36:43.567Z","phase":"Phase 2","brief_title":"A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway","source_id_and_acronym":"NCT02544997","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 amplification • EGFR expression • EGFR overexpression • AR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 amplification • EGFR expression • EGFR overexpression • AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pozenveo (poziotinib)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2020-07-07"},{"id":"91f25517-3648-4010-96ee-c139f5875d49","acronym":"CABA-BONE","url":"https://clinicaltrials.gov/study/NCT02512458","created_at":"2021-01-18T12:08:14.634Z","updated_at":"2024-07-02T16:36:50.251Z","phase":"Phase 2","brief_title":"Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer","source_id_and_acronym":"NCT02512458 - CABA-BONE","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" TP53 • AR • CYP17A1 • NKX3-1 • UBE2C","pipe":" | ","alterations":" AR expression • TP53 expression","tags":["TP53 • AR • CYP17A1 • NKX3-1 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cabazitaxel"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/29/2015","start_date":" 10/29/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/27/2019","study_completion_date":" 12/27/2019","last_update_posted":"2020-02-10"},{"id":"86014f68-4a3e-49b8-af42-63a4717724a7","acronym":"BARRIER-P","url":"https://clinicaltrials.gov/study/NCT02429193","created_at":"2021-01-18T11:37:20.503Z","updated_at":"2024-07-02T16:36:51.426Z","phase":"Phase 2","brief_title":"Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA","source_id_and_acronym":"NCT02429193 - BARRIER-P","lead_sponsor":"University Health Network, Toronto","biomarkers":" AR","pipe":" | ","alterations":" AR mutation • AR expression • AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation • AR expression • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 09/01/2019","primary_completion_date":" 09/01/2019","study_txt":" Completion: 09/01/2019","study_completion_date":" 09/01/2019","last_update_posted":"2020-01-13"},{"id":"51196d69-bb01-48c7-85a9-45a5653e9b8f","acronym":"PRX32","url":"https://clinicaltrials.gov/study/NCT03296124","created_at":"2021-01-18T16:16:53.886Z","updated_at":"2024-07-02T16:37:05.229Z","phase":"","brief_title":"Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)","source_id_and_acronym":"NCT03296124 - PRX32","lead_sponsor":"University of Florida","biomarkers":" AR","pipe":" | ","alterations":" AR expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/07/2017","start_date":" 12/07/2017","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2018-11-16"},{"id":"0c838d5c-86f9-41fd-9099-fb16d8eae5fa","acronym":"HORM","url":"https://clinicaltrials.gov/study/NCT03014973","created_at":"2021-01-18T14:50:15.228Z","updated_at":"2024-07-02T16:37:06.942Z","phase":"","brief_title":"Castration-resistant Prostate Cancer and Intra-prostatic Hormonal Status","source_id_and_acronym":"NCT03014973 - HORM","lead_sponsor":"Hopital Foch","biomarkers":" AR","pipe":" | ","alterations":" AR expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2018-09-13"}]